SINOVAC BIOTECH LTD
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $386.0M | $361.4M | $470.2M | $1.47B | $19.37B | $510.6M | $246.1M | $229.7M |
| Cost of Revenue | $124.0M | $140.7M | $146.9M | $658.2M | $988.9M | $67.2M | $32.5M | $24.7M |
| Gross Profit | $262.0M | $220.7M | $323.3M | $815.2M | $18.38B | $443.4M | $213.6M | $204.9M |
| Gross Margin | 67.9% | 61.1% | 68.8% | 55.3% | 94.9% | 86.8% | 86.8% | 89.2% |
| Operating Expenses | ||||||||
| Research & Development | $216.2M | $270.7M | $350.2M | $478.7M | $152.7M | $48.8M | $24.3M | $21.9M |
| SG&A Expense | $333.0M | $420.9M | $598.3M | $836.1M | $602.1M | $176.5M | $121.5M | $137.0M |
| Operating Income | $-490.1M | $-505.5M | $-714.0M | $-509.0M | $17.62B | $215.6M | $68.6M | $45.3M |
| Operating Margin | -127.0% | -139.9% | -151.9% | -34.5% | 91.0% | 42.2% | 27.9% | 19.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-262.1M | $42.8M | $-84.5M | $-48.5M | $17.57B | $216.6M | $70.8M | $46.6M |
| Income Tax Expense | $-63.3M | $2.2M | $36.4M | $11.5M | $3.45B | $31.4M | $5.6M | $10.5M |
| Net Income | $-198.8M | $40.7M | $-13.5M | $14.5M | $8.12B | $110.4M | $44.9M | $21.8M |
| Net Margin | -51.5% | 11.3% | -2.9% | 1.0% | 41.9% | 21.6% | 18.3% | 9.5% |
| EPS (Basic) | $-0.83 | $1.27 | $-0.19 | $0.20 | $113.54 | $1.06 | $0.42 | $0.34 |
| EPS (Diluted) | $-0.83 | $1.27 | $-0.19 | $0.20 | $113.44 | $0.97 | $0.41 | $0.34 |
| Shares Outstanding (Basic) | 71.9M | 71.9M | 71.8M | 71.7M | 71.5M | 98.9M | 94.9M | 64.7M |
| Shares Outstanding (Diluted) | 71.9M | 71.9M | 71.9M | 71.8M | 71.6M | 113.7M | 109.7M | 65.0M |
| Dividends Per Share | $55.00 | — | — | — | — | — | — | — |